免疫增强剂胸腺五肽临床超说明书用药调查分析  

Investigation and analysis of clinical off-label use of immune enhancer thymopentin

作　　者：柯玲玲 孙景环[1] 郑杨 马玉霞 张小亚 KE Lingling;SUN Jinghuan;ZHENG Yang;MA Yuxia;ZHANG Xiaoya(Chongqing Jiangjin District Hospital of Chinese Medicine,Chongqing 402260,China)

机构地区：[1]重庆市江津区中医院,重庆402260

出　　处：《现代医药卫生》2022年第18期3135-3137,共3页Journal of Modern Medicine & Health

基　　金：重庆市江津区科技局科研项目(Y2021016)。

摘　　要：目的 了解胸腺五肽在临床超说明书用药现状,为胸腺五肽作超说明书用药备案提供依据。方法 采用回顾性研究法,调查和审核某三甲中医院2020年11月1日至2021年10月31日门诊使用胸腺五肽的2 367张处方,整理出该药临床超说明书用药情况。结果 注射用胸腺五肽门诊处方超说明书用药发生率为75.58%(1 789/2 367),其中超适应证用药发生率为77.98%(1 395/1 789),超年龄范围用药发生率为1.17%(21/1 789),超用法用量发生率为62.88%(1 125/1 789)。结论 注射用胸腺五肽门诊用药存在超适应证、超剂量、超年龄范围等超说明书用药情况,需加强监控和管理,促进胸腺五肽超说明书用药备案。Objective To understand the status of clinical off-label use of thymopentin,so as to provide the basis for the record of off-label use of thymopentin.Methods A retrospective study method was used to investigate and review 2 367 prescriptions for outpatient use of thymopentin in this hospital from November 1st 2020 to October 31st 2021,and to sort out the clinical off-label use of the drug.Results The incidence of off-label use of thymopentin in outpatient prescriptions for injection was 75.58%(1 789/2 367).Among them,the incidence of off-indication drug use was 77.98%(1 395/1 789),the incidence of over-age drug use was 1.17%(21/1 789),and the incidence of over-use and dosage was 62.88%(1 125/1 789).Conclusion There are cases of off-label use of thymopentin for outpatient use,such as off-indication,over-dose and over-age range.It is necessary to strengthen monitoring and management to promote the recording of off-label use of thymopentin.

关 键 词：免疫增强剂 胸腺五肽 超说明书用药 

分 类 号：R97[医药卫生—药品]